Agilent Technologies, Inc.
A Healthcare Diagnostics & Research
Agilent Technologies, Inc.’s revenue for fiscal 2025 (year ended October 2025) was $6.9 billion, up 6.73% from fiscal 2024. In the quarter to July 2026, revenue grew 8.06%, EPS grew 8.47%, free cash flow grew 69.5% and total debt rose 8.81%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years.
Follow A
Agilent Technologies, Inc. (A) Return on equity
Agilent Technologies, Inc.'s return on equity over the twelve months to 31 July 2026 was 21.0%, up 0.4 percentage points from fiscal 2025 (20.6%). Over the past ten years it has ranged from 6.72% (fiscal 2018) to 23.6% (fiscal 2021); the current reading is higher than 55% of that period. That is above the Diagnostics & Research industry median of −2.92% and above the Healthcare sector median of −31.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | 20.6% | (1.33) |
| FY2024 | 22.0% | (0.29) |
| FY2023 | 22.2% | (1.21) |
| FY2022 | 23.5% | (0.13) |
| FY2021 | 23.6% | 8.63 |
| FY2020 | 15.0% | (8.04) |
| FY2019 | 23.0% | 16.27 |
| FY2018 | 6.72% | (8.34) |
| FY2017 | 15.1% | 4.08 |
| FY2016 | 11.0% | 2.51 |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| IDXX IDEXX Laboratories, Inc. compare | 74.2% |
| ILMN Illumina, Inc. compare | 32.4% |
| IQV IQVIA Holdings Inc. compare | 22.8% |
| A Agilent Technologies, Inc. | 21.0% |
| DGX Quest Diagnostics Incorporated compare | 14.0% |
| LH Labcorp Holdings Inc. compare | 11.7% |
| WAT Waters Corporation compare | 1.92% |
| NTRA Natera, Inc. compare | −12.5% |
| MTD Mettler-Toledo International, Inc. compare | −736.4% |
| Diagnostics & Research industry median | −2.92% |
| Healthcare sector median | −31.3% |
| Market median | 1.35% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on A
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement